Should radioimmunotherapy be an initial treatment option in advanced-stage follicular lymphoma? Commentary

Nature Clinical Practice Oncology

Volumn 2, Issue 7, 2005, Pages 346-347

  Portlock, Carol S ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody; Follicular lymphoma; Myelodysplasia; Radioimmunotherapy; Tositumomab

Indexed keywords

ANTIBODY; IBRITUMOMAB TIUXETAN; THYROID HORMONE; TOSITUMOMAB I 131;

ADVANCED CANCER; ARTHRALGIA; BLOOD TOXICITY; CANCER STAGING; CLINICAL TRIAL; DRUG DOSE REGIMEN; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPOTHYROIDISM; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SHORT SURVEY; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

EID: 31044442443     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0227     Document Type: Short Survey

References (4)

1. Solal-Celigny P et al. (2004) Follicular lymphoma international prognostic index. Blood 104: 1258-1265
2. Brice P et al. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15: 1110-1117
3. Cheson BD et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244
4. Horning SJ et al. (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23: 712-719